KEY MESSAGES

- Today, the Centers for Disease Control and Prevention (CDC) endorsed the Advisory Committee on Immunization Practices (ACIP)’s recommendation of the Novavax COVID-19 vaccine for primary series vaccination in adults ages 18 and older.

- Novavax is the first COVID-19 protein subunit vaccine that the CDC has recommended for use in the United States.
  - Protein subunit vaccines contain harmless pieces (proteins) of the COVID-19 virus alongside another ingredient called an adjuvant that helps the immune system respond to the virus in the future if exposed.
  - Vaccines using protein subunits have been used for more than 30 years in the United States, beginning with the first licensed hepatitis B vaccine. Other protein subunit vaccines used in the United States today include those to protect against influenza and acellular pertussis (whooping cough).

- ACIP’s vote—which follows the U.S. Food and Drug Administration (FDA)’s emergency use authorization—is for the use of the Novavax COVID-19 vaccine for adults ages 18 and older as a two-dose primary series. This recommendation is for all adults, including those who are moderately or severely immunocompromised.

- COVID-19 vaccines have undergone the most intense safety monitoring in U.S. history. Clinical research has demonstrated the safety and effectiveness of the Novavax COVID-19 vaccine.

- COVID-19 vaccines used in the U.S. continue to be highly effective in reducing the risk of severe disease, hospitalization, and death, including against the still-circulating Omicron variant and subvariants.
  - CDC recommends everyone ages 6 months and older get vaccinated against COVID-19, and that everyone ages 5 years and older get a COVID-19 booster, if eligible.
  - To learn if and when you or your child can get COVID-19 boosters, use CDC’s COVID-19 booster tool.